Virax Biolabs Group Limited Ordinary Shares (VRAX) Stock Analysis

Virax Biolabs Group Limited Ordinary Shares (VRAX) is a publicly traded company in the HEALTHCARE sector. It trades at $0.22, carries a market capitalization of $1.33M. This page summarizes the public market data, fundamentals, and frequently asked questions for VRAX, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Virax Biolabs Group Limited Ordinary Shares currently has a Neutral sentiment score of 0.11.

About Virax Biolabs Group Limited Ordinary Shares

Virax Biolabs Group Limited is a London-based biotechnology company dedicated to the prevention, detection, and management of viral diseases through cutting-edge diagnostic test kits and innovative medical technologies, including personal protective equipment (PPE). With a strong focus on immunology and a commitment to improving global healthcare outcomes, Virax is strategically positioned to address pressing public health challenges. The company aims to enhance its market presence while play...

GNG Research Analysis

GNG Research scores Virax Biolabs Group Limited Ordinary Shares (VRAX) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for VRAX.

Frequently Asked Questions

Does VRAX pay dividends?

Virax Biolabs Group Limited Ordinary Shares (VRAX) does not currently pay a regular dividend.

What is VRAX's market cap?

Virax Biolabs Group Limited Ordinary Shares (VRAX) has a market capitalization of $1.33M with a current stock price of $0.22.